Neisseria meningitidis

Neisseria meningitidis
Name	Neisseria meningitidis
Synonyms	Meningococcus
Caption	Gram stain of N. meningitidis showing Gram-negative diplococci.
Field	Infectious disease, Microbiology
Complications	Meningitis, Sepsis, Waterhouse–Friderichsen syndrome
Diagnosis	Cerebrospinal fluid analysis, Blood culture, Polymerase chain reaction
Prevention	Meningococcal vaccine
Treatment	Antibiotics (e.g., Ceftriaxone, Penicillin)

Neisseria meningitidis. It is a Gram-negative, aerobic bacterium that exclusively infects humans and is a leading cause of bacterial meningitis and septicemia worldwide. The organism is classified into multiple serogroups based on its polysaccharide capsule, with several being responsible for epidemic disease. Rapid diagnosis and treatment are critical, as infections can progress to death within hours.

Microbiology and classification

Neisseria meningitidis is a fastidious, oxidase-positive coccus that typically appears in pairs (diplococci) under microscopic examination. It is a member of the family Neisseriaceae and is closely related to Neisseria gonorrhoeae, the causative agent of Gonorrhea. Primary classification is based on the antigenic structure of its polysaccharide capsule, defining serogroups such as A, B, C, W-135, and Y. Further subtyping is achieved through analysis of outer membrane proteins, such as PorA and PorB, and multilocus sequence typing. The bacterium's genome was fully sequenced by researchers at The Sanger Institute, revealing a high degree of plasticity and frequent genetic exchange through transformation.

Pathogenesis and virulence factors

The pathogenesis of Neisseria meningitidis involves colonization of the nasopharynx, followed by invasion of the bloodstream and crossing of the Blood–brain barrier. Key virulence factors include the polysaccharide capsule, which confers resistance to complement-mediated killing and Phagocytosis. Pili facilitate initial attachment to epithelial cells, while outer membrane proteins like Opacity-associated protein (Opa) and OpC promote tight adhesion and invasion. The bacterium releases endotoxin, or Lipooligosaccharide (LOS), which triggers a massive systemic inflammatory response, leading to Septic shock and Disseminated intravascular coagulation. The Factor H binding protein is a critical virulence factor for serogroup B, enabling immune evasion.

Clinical manifestations and diagnosis

Clinical disease most commonly presents as acute bacterial Meningitis, characterized by fever, headache, stiff neck, and photophobia, or as Meningococcemia, a rapidly progressing septicemia often accompanied by a petechial or purpuric rash. Fulminant infection can lead to Waterhouse–Friderichsen syndrome, characterized by adrenal hemorrhage. Diagnosis is confirmed by isolating the bacterium from normally sterile sites; primary methods include Gram stain and culture of Cerebrospinal fluid obtained via Lumbar puncture or Blood culture. Rapid detection is also achieved through Polymerase chain reaction assays targeting specific genes, which are particularly useful after antibiotic administration. The Queckenstedt test is a historical maneuver related to CSF pressure.

Epidemiology and transmission

Neisseria meningitidis is transmitted through respiratory droplets and close contact, such as kissing or living in crowded conditions like Military barracks or College dormitories. The Meningitis Belt of sub-Saharan Africa, stretching from Senegal to Ethiopia, experiences regular epidemics of serogroup A, though vaccination campaigns have altered this pattern. Other serogroups, such as B, C, W, and Y, cause sporadic cases and outbreaks globally. Notable historical outbreaks include those among recruits at Camp Lejeune and pilgrims during the Hajj. Asymptomatic nasopharyngeal carriage, which can exceed 10% in populations, is a key reservoir for transmission and strain evolution.

Prevention and vaccination

Prevention relies primarily on vaccination. Several Meningococcal vaccines are available: conjugate vaccines target serogroups A, C, W, and Y (e.g., MenACWY), while protein-based vaccines, such as Bexsero and Trumenba, are effective against serogroup B. The World Health Organization recommends inclusion of conjugate vaccines in national immunization programs, especially in the Meningitis Belt. Chemoprophylaxis with antibiotics like Rifampin, Ciprofloxacin, or Ceftriaxone is used for close contacts of index cases to eliminate carriage. Public health agencies like the Centers for Disease Control and Prevention and Public Health England issue guidelines for outbreak management.

Treatment and antibiotic resistance

Empirical treatment for suspected meningococcal disease is a broad-spectrum cephalosporin, typically Ceftriaxone or Cefotaxime, often combined with Vancomycin until the causative agent is confirmed. Penicillin G remains effective for many isolates, but reduced susceptibility has been reported globally, monitored by programs like the Active Bacterial Core surveillance. Chloramphenicol is used in resource-limited settings. Management of complications requires intensive care support, often involving teams at institutions like the National Institutes of Health. Emerging resistance to ciprofloxacin, used for chemoprophylaxis, has been noted in isolates from North America and Europe, necessitating ongoing surveillance by bodies such as the European Centre for Disease Prevention and Control.

Category:Bacteria Category:Pathogens